October 25, 2016 1:27 PM ET


Company Overview of CureVac AG

Company Overview

CureVac AG, a biopharmaceutical company that develops messenger RNA (mRNA) therapeutics. It offers RNActive, which are mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases; RNArt molecular therapies that are designed to trigger the body's own production of therapeutic proteins; and RNAdjuvant RNA encoded antibodies. The company also researches and develops active ingredients for the treatment of cancer, as well as for protection against infectious diseases; and RNActive-based rabies vaccines. The company was founded in 2000 and is based in Tubingen, Germany.

Paul-Ehrlich-Straße 15

Tubingen,  72076


Founded in 2000


49 7071 9883 0


49 7071 9883 1101

Key Executives for CureVac AG

Co-Founder, Chief Executive Officer, Managing Director and Head of Business Development
Co-Founder and Chief Operating Officer
Chief Financial Officer
Chief Corporate Officer
Chief Medical Officer
Compensation as of Fiscal Year 2016.

CureVac AG Key Developments

CureVac AG Appoints Pierre Kemula as Chief Financial Officer

CureVac AG announced the appointment of Pierre Kemula as Chief Financial Officer. Mr. Kemula will join CureVac's management board and will be responsible for leading the company's financial and capital markets activities. Mr. Kemula joins CureVac after serving as Chief Financial Officer of Pixium Vision. During his tenure as CFO of Pixium Vision, Mr. Kemula was instrumental in the company's successful initial public offering on Euronext. Mr. Kemula began his career in consulting, with successful tenures at Roland Berger, Kea & Partners, Gemini Consulting and KPMG. He received his degree in Management Sciences from the London School of Economics in the United Kingdom.

CureVac AG Presents at 9th DVFA Life Science Conference, Jun-14-2016 02:05 PM

CureVac AG Presents at 9th DVFA Life Science Conference, Jun-14-2016 02:05 PM. Venue: DVFA Center, Mainzer Landstraße 37-39, 60329 Frankfurt am Main, Germany. Speakers: Franz-Werner Haas, Chief Corporate Officer.

CureVac Announces New Board Appoints

CureVac announced the expansion of its external Scientific Advisory Board (SAB). CureVac'sScientific Advisory Board includes the following experts across the company's core therapeutic categories: Prof. Carol J. Baker, MD, Professor of Pediatrics, Molecular Virology & Microbiology, Baylor College of Medicine, Houston; past-chair of the Advisory Committee on Immunization Practices (ACIP), president of the Infectious Diseases Society of America and the National Foundation for Infectious Diseases; Prof. Nina Bhardwaj, MD, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City; elected member of the American Society of Clinical Investigation and the American Association of Physicians; senior editor of the AACR Cancer Immunology Research journal; Ralf Clemens, MD, Chair of the SAB, former Vice President/Senior Vice President GSK Biologicals, Novartis Vaccines and Takeda Vaccines; advisor to the Bill & Melinda Gates Foundation and to the Africa Research Excellence Fund (AREF); member of CureVac's Supervisory Board; Michel De Wilde, PhD, member of the Board of Directors of the Infectious Disease Research Institute (IDRI) and of VBI; former Senior Vice President R&D at Sanofi Pasteur and Vice President Research GSK Biologicals; Prof. Dirk Jäger, MD, Director of Medical Oncology at the University Hospital of Heidelberg, Germany; leader of the research group "Applied Tumor Immunity" at the German Cancer Research Center; Prof. Karim Fizazi, MD, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France; President of the French Study Group of Carcinomas of Unknown Primary and associate editor of the European Journal of Cancer; Christopher Karp, MD, Director of Global Health Discovery & Translational Sciences at the Bill & Melinda Gates Foundation; Prof. Michael P. Manns, MD, Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany; Prof. Stanley Plotkin, MD, Emeritus Professor of the Wistar Institute and the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University; editor of the standard textbook "Vaccines"; Jean-Paul Prieels, PhD, Member of the Board of various Biotech companies including DNAlytics and Vaximm; former Senior Vice President R&D at GSK Biologicals; Prof. Hans-Georg Rammensee, PhD, Head of the Department of Immunology at the University of Tübingen, Germany; George R. Siber, MD, Chief Scientific Officer, ClearPath Vaccines Company and former Executive Vice President of Wyeth Pharma, CSO of Wyeth Vaccines and Director of the Massachusetts Biologic Laboratories; Prof. Daniel Speiser, MD, head of clinical tumor biology and immunotherapy group, Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland; Prof. Xiao-Ning Xu, MD, PhD, Chair in Human Immunology at the Imperial College London; previously Head of Novartis Vaccines Research China; Prof. Fred Zepp, MD, Medical Director and Chairman of the Department of Pediatrics, University Medical Center of the Johannes Gutenberg-University Mainz, Germany; past president of the German Society of Pediatrics and Adolescent Medicine; member of the STIKO at the Robert Koch Institute; and Gerd Zettlmeissl, PhD, Chairman Hilleman Laboratories, Board of Directors of Aeras and board member of various Biotech companies; former Managing Director of Chiron Behring and Chief Executive Officer of Intercell.

Similar Private Companies By Industry

Company Name Region
µ-bond GmbH Europe
4 Animals AlsterScience GmbH Europe
Across Barriers GmbH Europe
Actinodrug Pharmaceuticals GmbH Europe
ACTIPAC Biosystems GmbH Europe

Recent Private Companies Transactions

Private Placement
November 3, 2015

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CureVac AG, please visit www.curevac.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.